The largest database of trusted experimental protocols

Banamine s

Manufactured by Merck Group
Sourced in United States

Banamine®-S is a pharmaceutical product developed by Merck Group for use in veterinary medicine. It contains the active ingredient flunixin meglumine, which is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-pyretic properties. The product is intended for use in the treatment of inflammation and pain in animals.

Automatically generated - may contain errors

3 protocols using banamine s

1

Flunixin Meglumine Administration in Piglets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Piglets were randomly allotted to one of three treatment groups differing by route of administration: intramuscular (IM, n = 7), oral (PO, n = 8), and transdermal (TD, n = 8). A randomized block design ensured that an even number of males and females were assigned to each group. After group allocation, a pre-trial blood collection was performed on each piglet. One mortality resulted due to jugular vein hematoma, and therefore the intramuscular group consisted of 7 piglets. Flunixin meglumine was administered at a target dose of 2.2 mg/kg for IM (Banamine®-S, Merck Animal Health, Madison, NJ, USA) administration and a target dose of 3.3 mg/kg for PO and TD (Banamine®-S and Banamine® Transdermal, Merck Animal Health, Madison, NJ, USA). Piglets were weighed the day prior to drug administration to calculate drug dose for each pig. A single-use needle and syringe was used to administer FM in the musculature of the lateral neck, behind the ear. A new feeding tube was used for orogastric intubation and PO administration of FM, followed by a volume of water equal to the volume of the tube to ensure administration of the full dose. TD application consisted of a single-use syringe to apply FM to the dorsal midline skin between the shoulder blades.
+ Open protocol
+ Expand
2

Intranasal Flunixin Meglumine Administration in Piglets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immediately following IG injection, piglets enrolled in the FM treatment groups (CLF, SLF, CF, and SF) received 2.2 mg/kg of FM (Banamine-S; Merck Animal Health) in one nostril using a nasal IN mucosal atomization device attached to a 0.5-mL bottle mount vaccinator. The dose of FM used in this study has been recently validated. 20 (link) Piglets in the control group were handled in the same manner, and 0.2 mL of sterile saline was administered as described above.
+ Open protocol
+ Expand
3

Analgesic Efficacy in Piglet Castration

Check if the same lab product or an alternative is used in the 5 most similar protocols
At 6 days of age (±1 day) piglets were injected intramuscularly with one of 3 treatments; 0.4 mg/kg meloxicam (Meloxicam solution for injection 5 mg/mL, Putney, Inc., Portland, ME, USA), 2.2 mg/kg flunixin meglumine (Banamine-S®, Merck Animal Health, Summit, NJ, USA) or 3 mg/kg ketoprofen (Ketofen®, Zoetis, Inc., Kalamazoo, MI, USA). Treatment groups were assigned using a random number generator (Microsoft Excel 2016, Microsoft Corporation). The doses were chosen based on existing EU labels for piglets at castration (meloxicam and ketoprofen) or existing USA label dose for other indications in pigs (flunixin). Two hours after drug administration, the piglets were processed (defined in this study as only castrated and tail-docked). Piglets were restrained to expose the anogenital region of the piglet, while a second person performed the procedure. An incision was made on each side of the scrotum using a scalpel, the testicles were pulled from the surrounding tissue and the scalpel was used to cut the testicles free. The tail was then docked using standard tail clippers. Both the castration site and tail were sprayed with betadine to disinfect the wounds.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!